Skip to content
Screener

Precigen PGEN Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.9×-0.9×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
Gilead Sciences logo
Gilead SciencesGILD
2.2×+1.0×
Allogene Therapeutics logo
Allogene TherapeuticsALLO
0.3×+0.1×
Regenxbio logo
RegenxbioRGNX
+0.6×
Opko Health logo
Opko HealthOPK
0.0×

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$2.47B+358%
Enterprise value$2.56B+382%
P/S93.2×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Current ratio4.8×+1.3×

Where this comes from

Calculated from Precigen’s reported figures.

Based on the most recent quarter.

The source filing: Precigen’s 10-Q, filed May 13, 2026. Open the filing →

Filed
May 13, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356090-26-000017

FAQ

What is Precigen's debt-to-equity?
Precigen (PGEN) reported debt-to-equity of 4.9× in Q1 2026.
What is the long-term trend for Precigen's debt-to-equity?
Over 5 years (2020 to 2025), Precigen's debt-to-equity has grown at a 11.6% compound annual growth rate (CAGR), from 2.7× to 4.7×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Precigen's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude